Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15709182 | 0.98 | SIGMAR1 (0.56) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL31421250 | 0.88 | LMNA (0.60) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL20660205 | 0.86 | SIGMAR1 (0.56) | SIGMAR1LMNAPOLB | |
| SCHEMBL21315846 | 0.85 | SIGMAR1 (0.59) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL124097 | 0.85 | SIGMAR1 (0.59) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL2873355 | 0.85 | LMNA (0.57) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL2089619 | 0.85 | LMNA (0.57) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL2458948 | 0.84 | LMNA (0.59) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL3317019 | 0.84 | LMNA (0.59) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL7240012 | 0.84 | SIGMAR1 (0.58) | SIGMAR1LMNAPOLBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2127650-B1 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS INC (US) | 2018-12-05 | — | — | EP | disclosed |
| US-8557979-B2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120296084-A1 | Carbapenem Antibacterials with Gram-Negative Activity and Processes for Their Preparation | FOB SYNTHESIS, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-8232268-B2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100160284-A1 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY AND PROCESSES FOR THEIR PREPARATION | FOB SYNTHESIS, INC., (US) | 2010-06-24 | — | — | US | disclosed |
| US-7683049-B2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| EP-2127650-A2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB Synthesis, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1765326-A4 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY AND PROCESSES FOR THEIR PREPARATION | FOB SYNTHESIS INC (US) | 2009-05-13 | — | — | EP | disclosed |
| US-7259157-B2 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | MERCK & CO., INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259157-B2 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | MERCK & CO., INC. (US) | 2007-08-21 | — | — | US | disclosed |
| WO-2002080928-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-1095029-B1 | PIPERAZINE DERIVATIVES INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | UNIV PARIS 7 DENIS DIDEROT (FR) | 2002-09-18 | — | — | EP | disclosed |
| EP-1095029-A1 | PIPERAZINE DERIVATIVES INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | UNIVERSITE PARIS 7 - Denis DIDEROT (FR) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000001677-A1 | PIPERAZINE DERIVATIVES INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | UNIVERSITE PARIS 7 - DENIS DIDEROT (FR) | 2000-01-13 | — | — | WO | disclosed |
| EP-0288519-A4 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | — | 1992-04-15 | — | — | EP | disclosed |
| US-4965273-A | Certain 1-tertiary-butyl-naphthyridone carboxylic acid derivatives anti-bacterial agents | BRISTOL-MYERS COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| US-4954507-A | 1-tertiary-alkyl-substituted naphthyridine carboxylic acid antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0288519-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | Bristol-Myers Squibb Company (US) | 1988-11-02 | — | — | EP | disclosed |
| EP-0266576-A2 | 1-Tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents | Bristol-Myers Squibb Company (US) | 1988-05-11 | — | — | EP | disclosed |
| WO-1988002627-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120296084-A1 | Carbapenem Antibacterials with Gram-Negative Activity and Processes for Their Preparation | MGAM, GSK3B, GSK3A | SIGMAR1 1228/4885LMNA 1097/4885POLB 337/4885 |
| US-20100160284-A1 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY AND PROCESSES FOR THEIR PREPARATION | MGAM, GSK3B, GSK3A | SIGMAR1 1228/4885LMNA 1097/4885POLB 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.